150 related articles for article (PubMed ID: 12899538)
1. Efficacy and mechanism of action of 1alpha-hydroxy-24-ethyl-cholecalciferol (1alpha[OH]D5) in breast cancer prevention and therapy.
Hussain EA; Mehta RR; Ray R; Das Gupta TK; Mehta RG
Recent Results Cancer Res; 2003; 164():393-411. PubMed ID: 12899538
[TBL] [Abstract][Full Text] [Related]
2. Chemoprevention of mammary carcinogenesis by 1alpha-hydroxyvitamin D5, a synthetic analog of Vitamin D.
Mehta RG; Hussain EA; Mehta RR; Das Gupta TK
Mutat Res; 2003; 523-524():253-64. PubMed ID: 12628523
[TBL] [Abstract][Full Text] [Related]
3. Growth inhibition of carcinogen-transformed MCF-12F breast epithelial cells and hormone-sensitive BT-474 breast cancer cells by 1alpha-hydroxyvitamin D5.
Hussain-Hakimjee EA; Peng X; Mehta RR; Mehta RG
Carcinogenesis; 2006 Mar; 27(3):551-9. PubMed ID: 16195238
[TBL] [Abstract][Full Text] [Related]
4. Prevention of preneoplastic mammary lesion development by a novel vitamin D analogue, 1alpha-hydroxyvitamin D5.
Mehta RG; Moriarty RM; Mehta RR; Penmasta R; Lazzaro G; Constantinou A; Guo L
J Natl Cancer Inst; 1997 Feb; 89(3):212-8. PubMed ID: 9017001
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of ER and VDR is not sufficient to make ER-negative MDA-MB231 breast cancer cells responsive to 1alpha-hydroxyvitamin D5.
Peng X; Jhaveri P; Hussain-Hakimjee EA; Mehta RG
Carcinogenesis; 2007 May; 28(5):1000-7. PubMed ID: 17130524
[TBL] [Abstract][Full Text] [Related]
6. Differentiation of human breast carcinoma cells by a novel vitamin D analog: 1alpha-hydroxyvitamin D5.
Mehta RR; Bratescu L; Graves JM; Green A; Mehta RG
Int J Oncol; 2000 Jan; 16(1):65-73. PubMed ID: 10601550
[TBL] [Abstract][Full Text] [Related]
7. Regulation of steroid receptor expression by 1alpha-hydroxyvitamin D5 in hormone-responsive breast cancer cells.
Hussain-Hakimjee EA; Mehta RG
Anticancer Res; 2009 Sep; 29(9):3555-61. PubMed ID: 19667148
[TBL] [Abstract][Full Text] [Related]
8. MART-10, a less calcemic vitamin D analog, is more potent than 1α,25-dihydroxyvitamin D3 in inhibiting the metastatic potential of MCF-7 breast cancer cells in vitro.
Chiang KC; Chen SC; Yeh CN; Pang JH; Shen SC; Hsu JT; Liu YY; Chen LW; Kuo SF; Takano M; Kittaka A; Sun CC; Juang HH; Chen TC
J Steroid Biochem Mol Biol; 2014 Jan; 139():54-60. PubMed ID: 24125734
[TBL] [Abstract][Full Text] [Related]
9. Stage-specific inhibition of mammary carcinogenesis by 1alpha-hydroxyvitamin D5.
Mehta RG
Eur J Cancer; 2004 Oct; 40(15):2331-7. PubMed ID: 15454260
[TBL] [Abstract][Full Text] [Related]
10. Dissociation of vitamin D3 and anti-estrogen mediated growth regulation in MCF-7 breast cancer cells.
Nolan E; Donepudi M; VanWeelden K; Flanagan L; Welsh J
Mol Cell Biochem; 1998 Nov; 188(1-2):13-20. PubMed ID: 9823006
[TBL] [Abstract][Full Text] [Related]
11. Chemoprevention of chemically-induced mammary and colon carcinogenesis by 1alpha-hydroxyvitamin D5.
Murillo G; Mehta RG
J Steroid Biochem Mol Biol; 2005 Oct; 97(1-2):129-36. PubMed ID: 16051482
[TBL] [Abstract][Full Text] [Related]
12. Cell cycle arrest and apoptosis induced by 1α,25(OH)2D3 and TX 527 in Kaposi sarcoma is VDR dependent.
González-Pardo V; Suares A; Verstuyf A; De Clercq P; Boland R; de Boland AR
J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt A():197-200. PubMed ID: 24316429
[TBL] [Abstract][Full Text] [Related]
13. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines.
Koike M; Koshizuka K; Kawabata H; Yang R; Taub HE; Said J; Uskokovic M; Tsuruoka N; Koeffler HP
Anticancer Res; 1999; 19(3A):1689-97. PubMed ID: 10470102
[TBL] [Abstract][Full Text] [Related]
14. Antiproliferative signalling by 1,25(OH)2D3 in prostate and breast cancer is suppressed by a mechanism involving histone deacetylation.
Banwell CM; Singh R; Stewart PM; Uskokovic MR; Campbell MJ
Recent Results Cancer Res; 2003; 164():83-98. PubMed ID: 12899515
[TBL] [Abstract][Full Text] [Related]
15. Androgen Receptor regulation of Vitamin D receptor in response of castration-resistant prostate cancer cells to 1α-Hydroxyvitamin D5 - a calcitriol analog.
Mooso B; Madhav A; Johnson S; Roy M; Moore ME; Moy C; Loredo GA; Mehta RG; Vaughan AT; Ghosh PM
Genes Cancer; 2010 Nov; 1(9):927-940. PubMed ID: 21552398
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a vitamin D3-resistant MCF-7 cell line.
Narvaez CJ; Vanweelden K; Byrne I; Welsh J
Endocrinology; 1996 Feb; 137(2):400-9. PubMed ID: 8593782
[TBL] [Abstract][Full Text] [Related]
17. Induction of differentiation by 1alpha-hydroxyvitamin D(5) in T47D human breast cancer cells and its interaction with vitamin D receptors.
Lazzaro G; Agadir A; Qing W; Poria M; Mehta RR; Moriarty RM; Das Gupta TK; Zhang XK; Mehta RG
Eur J Cancer; 2000 Apr; 36(6):780-6. PubMed ID: 10762752
[TBL] [Abstract][Full Text] [Related]
18. 1alpha,25-Dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells.
Swami S; Krishnan AV; Feldman D
Clin Cancer Res; 2000 Aug; 6(8):3371-9. PubMed ID: 10955825
[TBL] [Abstract][Full Text] [Related]
19. 25-Hydroxyvitamin D3 is a natural chemopreventive agent against carcinogen induced precancerous lesions in mouse mammary gland organ culture.
Peng X; Hawthorne M; Vaishnav A; St-Arnaud R; Mehta RG
Breast Cancer Res Treat; 2009 Jan; 113(1):31-41. PubMed ID: 18205042
[TBL] [Abstract][Full Text] [Related]
20. The anti-proliferative effects of 1alpha,25(OH)2D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression.
Campbell MJ; Gombart AF; Kwok SH; Park S; Koeffler HP
Oncogene; 2000 Oct; 19(44):5091-7. PubMed ID: 11042697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
